7 Quotes by John LaMattina

More than one billion people around the world suffer from neurological conditions and diseases, and finding new, more effective treatments for patients is a high priority for Pfizer research and development.

We're of a size and can do enough different things that we're not putting all our bets on one specific area,

I think this will be the norm. When you have something new, there is the theoretical potential for harm.

We recognize that many diseases we aim to treat have a strong genetic component. Additionally, we know some patients taking medicines show efficacy or experience side-effects, while others do not. Our understanding of all this has improved greatly but these areas remain as significant challenges in drug development.

We will be the first out there and for a while.

Is the public more cynical? Yes. There's a perception that we don't bring much to the party.

I'm a big believer in size, ... When you're a smaller company, as we were 27 years ago when I started, you don't necessarily have the resources to invest in things outside your immediate expertise. But as we've gotten bigger and become more resource-rich we've been able to expand.